BioSpace News Archive

AIM ImmunoTech, announced that it will be presenting at the SNN Network Virtual Investor Conference on Monday, August 3, 2020 at 1:30 PM EST.

Merus N.V. (Nasdaq: MRUS), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics™), today announced the appointment of Andrew Joe, M.D., as Chief Medical Officer. Dr. Joe is a medical oncologist with extensive expertise in the development of immuno-oncology, antibody and targeted cancer therapies, and with broad leadership experience in oncolog

Todos Medical Ltd. (OTCQB: TOMDF) , an in vitro diagnostics company focused on distributing comprehensive solutions for COVID-19 screening and diagnosis, and developing blood tests for the early detection of cancer and Alzheimer’s disease, today announced the Company has entered into a contract to supply NJ-based laboratory Best Suppl

INOVIO (NASDAQ: INO) announced today that second quarter 2020 financial results will be released after the market close on August 10, 2020 . Following the release, the Company will host a live conference call and webcast at 4:30 p.m. ET to discuss financial results and provide a general business update, including the company

Masimo (NASDAQ: MASI) today announced a significant expansion to the Masimo SafetyNet™ platform with the introduction of Radius Tº™, a wearable, wireless sensor that provides continuous body temperature measurements. By augmenting the already powerful Masimo SafetyNet, which features Radius PPG™ tetherless pulse o

Prevalence of insomnia has recorded a tremendous surge in the recent past, however development of an effective treatment procedure for insomnia has not yet been realized.

The global market for human microbiome is projected to showcase a considerable potential in the coming years of the forecast period.

- Plans to Initiate Phase 1 Clinical Trial This Year - Expands Corporate Advisors with Board of Directors and Scientific Advisory Board Appointments

400 Patients Expected to be Enrolled in CPRIT-Backed Artificial Intelligence Development Study in Breast Cancer

MediciNova, Inc. announced an agreement with BioComo and Mie University for joint development of a SARS-CoV-2 vaccine using BC-PIV, a human parainfluenza virus type 2 vector developed by BioComo and Tetsuya Nosaka, M.D., Ph.D., professor of the Department of Microbiology and Molecular Genetics, Mie University Graduate School of Medicine.